When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...
In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...
US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation ...
The proposed Biosecure Act as well as the diversification of American and European firms away from China are expected to help ...
Forecast: Pharma and healthcare mutual funds have topped with an average return of 38.05% in 2024. HDFC Pharma and Healthcare ...
GlobalData on MSN3d
WuXi Biologics to sell Ireland-based vaccine site to MSD for $500mThe transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s ...
Investors also drew comfort from positive management commentary on increased client inquiries and on-site customer visits, ...
The transaction – announced on Christmas Eve – comes after WuXi AppTec has been thrust into the US political spotlight as a ...
The Biosecure Act was left out of a key US defence bill that passed in the House last week, in a major win for Chinese CDMOs. Shares in WuXi AppTec (Shanghai, China) opened 10.5% higher on ...
JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback